CoChat

SIRT1 Regulates Hepatocyte Lipid Metabolism through Activating AMP-activated Protein Kinase

Open access
Hou, Xiuyun, Xu, Shanqin, Maitland-Toolan, Karlene A., Sato, Kaori, Jiang, Bingbing, Ido, Yasuo, Lan, Fan, Walsh, Kenneth, Wierzbicki, Michel, Verbeuren, Tony J., Cohen, Richard A., Zang, Mengwei · 2008 · Journal of Biological Chemistry

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Abstract

Resveratrol may protect against metabolic disease through activating SIRT1 deacetylase. Because we have recently defined AMPK activation as a key mechanism for the beneficial effects of polyphenols on hepatic lipid accumulation, hyperlipidemia, and atherosclerosis in type 1 diabetic mice, we hypothesize that polyphenol-activated SIRT1 acts upstream of AMPK signaling and hepatocellular lipid metabolism. Here we show that polyphenols, including resveratrol and the synthetic polyphenol S17834, increase SIRT1 deacetylase activity, LKB1 phosphorylation at Ser(428), and AMPK activity. Polyphenols substantially prevent the impairment in phosphorylation of AMPK and its downstream target, ACC (acetyl-CoA carboxylase), elevation in expression of FAS (fatty acid synthase), and lipid accumulation in human HepG2 hepatocytes exposed to high glucose. These effects of polyphenols are largely abolished by pharmacological and genetic inhibition of SIRT1, suggesting that the stimulation of AMPK and lipid-lowering effect of polyphenols depend on SIRT1 activity. Furthermore, adenoviral overexpression of SIRT1 stimulates the basal AMPK signaling in HepG2 cells and in the mouse liver. AMPK activation by SIRT1 also protects against FAS induction and lipid accumulation caused by high glucose. Moreover, LKB1, but not CaMKKbeta, is required for activation of AMPK by polyphenols and SIRT1. These findings suggest that SIRT1 functions as a novel upstream regulator for LKB1/AMPK signaling and plays an essential role in the regulation of hepatocyte lipid metabolism. Targeting SIRT1/LKB1/AMPK signaling by polyphenols may have potential therapeutic implications for dyslipidemia and accelerated atherosclerosis in diabetes and age-related diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/jbc.m802187200

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE1 PharmacologicalactivationofSIRT1byresveratrolpreventsthedecreaseinAMPKactivityand elevation in FAS expression and triglyceride level in human HepG2 hepatocytes exposed to high glucose. A , the dose-response effect of resveratrol on in vitro SIRT1 deacetylase activity. Fluor de Lys fluorescence deacetylase assays were preformed with human recombinant SIRT1, using a synthetic acetylated Lys 382 p53 peptide and NAD as substrates in the absence or presence of increasing concentrations (10-100 𝛍 M) of resveratrol as described under 'Experimental Procedures.' SIRT1 activity was expressed as arbitrary fluorescence units relative to the control (mean ± S.E., n = 4). *, p < 0.05 versus control. B , resveratrol prevents the inhibition of AMPK caused by high glucose in a dose-dependent manner. HepG2 cells were maintained in serum-free DMEMcontainingnormalglucoseovernightandincubatedfor24hwithoutorwithincreasingconcentrations (1-50 𝛍 M) of resveratrol in the absence or presence of 30 mM D-glucose (high glucose). Representative immunoblotting analysis with antibodies against AMPK 𝛂 phosphorylated at Thr 172 (pAMPK) and total AMPK 𝛂 1 or -𝛂 2 for loading controls, respectively, is shown. Immunoblots with anti-SIRT1 antibody show the existence of ∼ 120kDaofendogenousSIRT1inHepG2cellsandnodetectablechangeinSIRT1throughouttreatment. C and D , high glucose increases and resveratrol suppresses expression of FAS. Expression of FAS was analyzed by immunoblots with anti-FAS and normalized to 𝛃 -actin level and presented as the -fold change (mean ± S.E., n = 3). E , resveratrol protects against high glucose-induced triglyceride accumulation. Intracellular triglyceride contents were measured and expressed as 𝛍 g of lipid/mg of protein (the mean ± S.E., n = 4) as described under 'Experimental Procedures.' *, p < 0.05 versus normal glucose; #, p < 0.05 versus high glucose alone.
FIGURE1 PharmacologicalactivationofSIRT1byresveratrolpreventsthedecreaseinAMPKactivityand elevation in FAS expression and triglyceride level in human HepG2 hepatocytes exposed to high glucose. A , the dose-response effect of resveratrol on in vitro SIRT1 deacetylase activity. Fluor de Lys fluorescence deacetylase assays were preformed with human recombinant SIRT1, using a synthetic acetylated Lys 382 p53 peptide and NAD as substrates in the absence or presence of increasing concentrations (10-100 𝛍 M) of resveratrol as described under 'Experimental Procedures.' SIRT1 activity was expressed as arbitrary fluorescence units relative to the control (mean ± S.E., n = 4). *, p < 0.05 versus control. B , resveratrol prevents the inhibition of AMPK caused by high glucose in a dose-dependent manner. HepG2 cells were maintained in serum-free DMEMcontainingnormalglucoseovernightandincubatedfor24hwithoutorwithincreasingconcentrations (1-50 𝛍 M) of resveratrol in the absence or presence of 30 mM D-glucose (high glucose). Representative immunoblotting analysis with antibodies against AMPK 𝛂 phosphorylated at Thr 172 (pAMPK) and total AMPK 𝛂 1 or -𝛂 2 for loading controls, respectively, is shown. Immunoblots with anti-SIRT1 antibody show the existence of ∼ 120kDaofendogenousSIRT1inHepG2cellsandnodetectablechangeinSIRT1throughouttreatment. C and D , high glucose increases and resveratrol suppresses expression of FAS. Expression of FAS was analyzed by immunoblots with anti-FAS and normalized to 𝛃 -actin level and presented as the -fold change (mean ± S.E., n = 3). E , resveratrol protects against high glucose-induced triglyceride accumulation. Intracellular triglyceride contents were measured and expressed as 𝛍 g of lipid/mg of protein (the mean ± S.E., n = 4) as described under 'Experimental Procedures.' *, p < 0.05 versus normal glucose; #, p < 0.05 versus high glucose alone.CC-BY · From the PDF
Image 2
CC-BY · From the PDF
Image 3
CC-BY · From the PDF
FIGURE 4 Polyphenol-induced AMPK activation and lipid reduction is abolished by overexpression of a catalytically inactive mutant of SIRT1 (SIRT1H355A) in HepG2 cells. A , a representative immunoblot of overexpression of an adenovirus vector encoding a catalytically inactive SIRT1 mutant in HepG2 cells is shown. B , polyphenol-stimulated AMPK phosphorylation is abolished by the SIRT1H355A mutant under normal glucose conditions. HepG2 cells were infected for 48 h with Ad-GFP or Ad-SIRT1H355A, followed by treatment with S17834 (10 𝛍 M) or resveratrol (50 𝛍 M) for 1 h. C and D , polyphenol-stimulated AMPK signaling is diminished by the SIRT1H355A mutant under high glucose conditions. HepG2 cells infected with Ad-GFP or Ad-SIRT1H355A were quiesced in serum-free medium overnight and treated for 24 h without or with 10 𝛍 Mof resveratrol or S17834 in the presence of high glucose. E , the lipid-lowering effect of resveratrol is attenuated by the SIRT1H355A mutant. *, p < 0.05 versus normal glucose in cells expressing GFP; #, p < 0.05 versus high glucose alone in cells expressing GFP; ##, p < 0.05 versus polyphenol treatment in cells expressing GFP (mean ± S.E., n = 4).
FIGURE 4 Polyphenol-induced AMPK activation and lipid reduction is abolished by overexpression of a catalytically inactive mutant of SIRT1 (SIRT1H355A) in HepG2 cells. A , a representative immunoblot of overexpression of an adenovirus vector encoding a catalytically inactive SIRT1 mutant in HepG2 cells is shown. B , polyphenol-stimulated AMPK phosphorylation is abolished by the SIRT1H355A mutant under normal glucose conditions. HepG2 cells were infected for 48 h with Ad-GFP or Ad-SIRT1H355A, followed by treatment with S17834 (10 𝛍 M) or resveratrol (50 𝛍 M) for 1 h. C and D , polyphenol-stimulated AMPK signaling is diminished by the SIRT1H355A mutant under high glucose conditions. HepG2 cells infected with Ad-GFP or Ad-SIRT1H355A were quiesced in serum-free medium overnight and treated for 24 h without or with 10 𝛍 Mof resveratrol or S17834 in the presence of high glucose. E , the lipid-lowering effect of resveratrol is attenuated by the SIRT1H355A mutant. *, p < 0.05 versus normal glucose in cells expressing GFP; #, p < 0.05 versus high glucose alone in cells expressing GFP; ##, p < 0.05 versus polyphenol treatment in cells expressing GFP (mean ± S.E., n = 4).CC-BY · From the PDF
Image 5
CC-BY · From the PDF
Image 6
CC-BY · From the PDF
Image 7
CC-BY · From the PDF
FIGURE 8 Proposed scheme for the role of SIRT1-activating polyphenols in the regulation of AMPK signaling and hepatocyte lipid metabolism. SIRT1-activating polyphenols, such as resveratrol and S17834, stimulate LKB1 phosphorylation as well as AMPK phosphorylation and activation. Similarly, overexpression of wild type SIRT1 also increases AMPK phosphorylation, which in turn increases ACC phosphorylation and inhibits ACC activity. As a consequence, decreased production of malonyl-CoA results in up-regulation of fatty acid oxidation as well as down-regulation of fatty acid synthesis, thereby leading to hepatocyte lipid reduction. On the other hand, activation of AMPK by polyphenols inhibits glucose-induced expression of FAS, which contributes to the reduction in triglycerides through inhibition of fatty acid biosynthesis. Moreover, SIRT1 is required for the effects of polyphenols on AMPKandlipids, since the beneficial effects of polyphenols are mimicked by overexpression of wild type SIRT1 and abrogated by inhibition of SIRT1, such as the inactive SIRT1 mutant (SIRT1H355A), shRNA SIRT1, or inhibitors of SIRT1. Importantly, the stimulation of AMPK and the lipid-lowering effect of SIRT1 are abolished by DN-AMPK, suggesting that AMPK acts as a novel functional downstream regulator for the metabolic effect of SIRT1. In addition, polyphenols and SIRT1 stimulate AMPK via an LKB1-dependent mechanism. Therefore, SIRT1/LKB1/AMPK signaling may be considered a novel molecular mechanism for potential therapeutic effects of polyphenols on hepatic lipid accumulation in diabetes and age-related metabolic disorders.
FIGURE 8 Proposed scheme for the role of SIRT1-activating polyphenols in the regulation of AMPK signaling and hepatocyte lipid metabolism. SIRT1-activating polyphenols, such as resveratrol and S17834, stimulate LKB1 phosphorylation as well as AMPK phosphorylation and activation. Similarly, overexpression of wild type SIRT1 also increases AMPK phosphorylation, which in turn increases ACC phosphorylation and inhibits ACC activity. As a consequence, decreased production of malonyl-CoA results in up-regulation of fatty acid oxidation as well as down-regulation of fatty acid synthesis, thereby leading to hepatocyte lipid reduction. On the other hand, activation of AMPK by polyphenols inhibits glucose-induced expression of FAS, which contributes to the reduction in triglycerides through inhibition of fatty acid biosynthesis. Moreover, SIRT1 is required for the effects of polyphenols on AMPKandlipids, since the beneficial effects of polyphenols are mimicked by overexpression of wild type SIRT1 and abrogated by inhibition of SIRT1, such as the inactive SIRT1 mutant (SIRT1H355A), shRNA SIRT1, or inhibitors of SIRT1. Importantly, the stimulation of AMPK and the lipid-lowering effect of SIRT1 are abolished by DN-AMPK, suggesting that AMPK acts as a novel functional downstream regulator for the metabolic effect of SIRT1. In addition, polyphenols and SIRT1 stimulate AMPK via an LKB1-dependent mechanism. Therefore, SIRT1/LKB1/AMPK signaling may be considered a novel molecular mechanism for potential therapeutic effects of polyphenols on hepatic lipid accumulation in diabetes and age-related metabolic disorders.CC-BY · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 57 references

Cited by

Items 101–200 of 790

Metadata

Authors
Hou, X., Xu, S., Maitland-Toolan, K. A., Sato, K., Jiang, B., Ido, Y., Lan, F., Walsh, K., Wierzbicki, M., Verbeuren, T. J., Cohen, R. A., & Zang, M.
Affiliations
  • Boston University (US)
  • Institut de Recherches Internationales Servier (France) (FR)
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2008-07
Volume
283
Issue
29
Pages
20015-20026
ISSN
0021-9258 (ISSN-L)
OpenAlex
W1973163466
Cited by
778
References
57
Citations by year
2026: 15 · 2025: 21 · 2024: 26 · 2023: 29 · 2022: 38 · 2021: 33 · 2020: 38 · 2019: 42 · 2018: 52 · 2017: 49 · 2016: 50 · 2015: 50 · 2014: 60 · 2013: 71 · 2012: 54
FWCI
20.35
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Biological Chemistry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Servier
  • National Institutes of Health (P01 HL 68758)
  • Institut de Recherches Servier
  • National Institute on Aging (R01 AG-27080, R01AG027080)
  • National Heart, Lung, and Blood Institute (P01HL068758, P01-HL68758)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK 76942, R01DK076942)
Topics
  • Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
Keywords
SIRT1, AMPK, LKB1, polyphenols, resveratrol, hepatocyte lipid metabolism, hepatic lipid accumulation, fatty acid synthase, acetyl-CoA carboxylase, high glucose, dyslipidemia, atherosclerosis, type 1 diabetes, CaMKKβ
MeSH terms
AMP-Activated Protein Kinase Kinases, Animals, Cell Line, Enzyme Activation, Flavonoids, Glucose, Humans, Multienzyme Complexes, Phenols, Signal Transduction, Gene Expression Regulation, Enzymologic, Protein Serine-Threonine Kinases, Hepatocytes, RNA Interference, Sirtuins, Lipid Metabolism, Mice, Focal Adhesion Protein-Tyrosine Kinases, Calcium-Calmodulin-Dependent Protein Kinase Kinase, AMP-Activated Protein Kinases, Sirtuin 1, Polyphenols

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.